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Correspondence to:Attention deficit/hyperactivity disorder (ADHD) is a childhood
onset disorder, prevalent in 5.3% of children and 1–4% of adults.
ADHD is highly heritable, with a burden of large (>500Kb) copy
number variants (CNVs) identified among individuals withADHD.
However, how such CNVs exert their effects is poorly understood.
Weexaminedthegenesaffectedby71 large, rare,andpredominantly
inherited CNVs identified among 902 individuals with ADHD. We
applied both mouse-knockout functional enrichment analyses,
exploiting behavioral phenotypes arising from the determined
disruption of 1:1 mouse orthologues, and human brain-specific
spatio-temporal expression data to uncover molecular pathways
commonamonggenescontributingtoenrichedphenotypes.Twenty
-twopercentof genesduplicated in individualswithADHDthathad
mouse phenotypic information were associated with abnormal
learning/memory/conditioning (“l/m/c”) phenotypes. Although not
observed in a second ADHD-cohort, we identified a similar enrich-
ment among genes duplicated by eight de novo CNVs present in
eight individuals with Hyperactivity and/or Short attention span
(“Hyperactivity/SAS”, the ontologically-derived phenotypic compo-
nents of ADHD). In the brain, genes duplicated in patients with
ADHD and Hyperactivity/SAS and whose orthologues’ disruption
yields l/m/c phenotypes in mouse (“candidate-genes”), were co-
expressed with one another and with genes whose orthologues’
mouse models exhibit hyperactivity. Moreover, genes associated
with hyperactivity in the mouse were significantly more co-
expressed with ADHD candidate-genes than with similarly identi-
fied genes from individuals with intellectual disability. Our findings
support an etiology for ADHD distinct from intellectual disability,
and mechanistically related to genes associated with hyperactivity
phenotypes in other mammalian species.
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Attention deficit/hyperactivity disorder (ADHD) is a common neu-
ropsychiatric disorder with childhood onset, prevalent in approxi-2015 The Authors. American Journal of Medical Genetics Part B: Nmately 5% of children [Polanczyk et al., 2007] and 1–4% of adults
[Kessler et al., 2006;Fayyadetal., 2007].Thepersonal andsocietal costs
of the disorder are high, including education and employment prob-
lems[Pelhametal., 2007;Danckaerts et al., 2010;Adamouet al., 2013],
aswell as drug andalcohol addiction [Biedermanet al., 1995; Schachar
andTannock, 1995; Thapar et al., 2001;Ohlmeier et al., 2008]. ADHD
has two subtypes—predominantly inattentive and predominantly
hyperactive-impulsive—which may be present singularly or together
in an individualwith thedisorder (Diagnostic andStatisticalManual of
MentalDisorders [4thed., text rev.;DSM-IV-TR;AmericanPsychiatric
Association TR]). In addition, there is significant heterogeneity in the
underlying neuropsychological impairments and comorbidities
among individuals with ADHD [Spencer et al., 2007; Wahlstedt
et al., 2009; Larson et al., 2011].
Family and twin studies have estimated that ADHD has high
heritability, ~76% [Faraone et al., 2005], but the genetic etiology ofeuropsychiatric Genetics Published by Wiley Periodicals, Inc. 97
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of common single nucleotide polymorphisms (SNPs) to pheno-
typic variance is around 25–28% [Cross-Disorder Group of
the Psychiatric Genomics Consortium, 2013], while the additive
effects of significantly associated candidate genes contribute only
3.3% to phenotypic variance [Kuntsi et al., 2006]. Furthermore,
linkage analyses have confirmed only one associated region on
chromosome 16q21–24 [Zhou et al., 2008], and genome-wide
association studies (GWAS) have not provided significant novel
associations between any individual SNP and ADHD [Lasky-Su
et al., 2008; Lesch et al., 2008; Neale et al., 2008; Franke et al., 2009;
Mick et al., 2010; Neale et al., 2010]. These findings, combined
with evidence for a significant polygenic component in the etiology
of ADHD [Cross-Disorder Group of the Psychiatric Genomics
Consortium, 2013; Hamshere et al., 2013; Yang et al., 2013],
raise the hypothesis that rare variants inmany genesmay contribute
to the disorder. Corroboratively, a significantly increased rate of
rare, large (>500 Kb) copy number variants (CNVs) was found in
patients with ADHD compared to controls [Williams et al., 2010;
Stergiakouli et al., 2012;Williams et al., 2012], although this finding
was not replicated in other reports [Elia et al., 2010; Lionel et al.,
2011; Jarick et al., 2014]. The contribution of CNVs to the aetiology
of ADHD remains poorly understood.
In this study, we explored the hypothesis that distinct CNVs give
rise to ADHD by affecting genes participating in shared biological
processes, the disruption of which predisposes towards the disor-
der. We applied mouse-knockout functional enrichment analyses
to genes disrupted by 71 large CNVs (>500 Kb) identified among a
meta-cohort of 902 individuals with ADHD [Elia et al., 2010;
Williams et al., 2010; Lionel et al., 2011] and observed a signifi-
cant enrichment, among copy number gains, of genes whose 1:1
orthologues’ disruption yields an abnormal learning/memory/TABLE I. Distribution of CNVs Among Ind
Cohort CNVs CNVs> 500 Kb Gains Gains
(A) ADHD-meta cohort
Elia cohort 222 14 64
Williams cohort 40 40 30
Lionel cohort 306 17 149
Total 568 71 243
(B) ADHD-replication cohort
Stergiakouli cohort 47 47 35
Williams (2) cohort 460 89 299
Jarick cohort 51 51 34
Total 558 187 368 1
(C) Control cohort
Shaikh cohort 24478 3327
(A) CNVs arising in the genomes of individuals from three cohorts of patientswith ADHD. The three cohor
cohort”), Williams et al. [Williams et al., 2010] (“Williams cohort”), and Lionel et al. [Lionel et al., 2011]
counts are shown for gains and losses. The last column shows the total number of individualswhose gen
of patientswith ADHD. These cohorts comprise the “ADHD-replication cohort” andwere published by Ster
(“Williams (2) cohort”), and Jarick et al. [Jarick et al., 2014] (“Jarick cohort”). (C) CommonCNVsarising
Shaikh et al. [Shaikh et al., 2009]. CNVs from this control cohort were not filtered by length, so we do
individuals harboring a CNV of any length.
aaThe number of individuals contributing CNVs was not published in [Williams et al., 2012]; insteadconditioning (“l/m/c”) phenotype in mouse. We observed a similar
enrichment among eight large de novo duplications present in eight
individuals described in the DECIPHER database withHyperactiv-
ity and/or Short attention span (“Hyperactivity/SAS”), the ontolog-
ically-derived phenotypic components of ADHD [Firth et al., 2009;
Robinson and Mundlos, 2010]. Genes duplicated in patients with
ADHD andHyperactivity/SAS, and whose orthologues’ disruption
yields l/m/c in the mouse were significantly co-expressed in the
brain. Furthermore, these genes were significantly co-expressed
with genes whose orthologues’ disruption cause hyperactivity phe-
notypes in the mouse, and were significantly more co-expressed
than similarly identified genes from individuals with intellectual
disability, supporting an ADHD-specific expression association.
MATERIALS AND METHODS
CNV Data for Patients With ADHD
We obtained data pertaining to rare, predominantly inherited,
CNVs in 902 patients with ADHD (the “ADHD-meta cohort”)
from three studies: 335 cases reported by Elia et al. [Elia et al.,
2010] (“Elia cohort”), 319 cases reported by Williams et al.
[Williams et al., 2010] (“Williams cohort”), and 248 cases reported
byLionel et al. [Lionel et al., 2011] (“Lionel cohort”) (Supplemental
Table SI). Where necessary, CNV coordinates were lifted to Build
36 using liftOver [Hinrichs et al., 2006]. We restricted our analysis
to 71 CNVs> 500 Kb contributed by 67 individuals (Table IA).
During this study, three further data sets were published of rare
CNVs in an additional 1,842 patients not included in the ADHD-
meta cohort [Jarick et al., 2014; Stergiakouli et al., 2012; Williams
et al., 2012] (Supplemental Table SI); we combined them into an
“ADHD-replication cohort” consisting of 187 CNVs> 500Kb,
from up to 180 individuals (see Table IB).ividuals in ADHD and Control Cohorts
> 500 Kb Losses Losses> 500 Kb
Individuals contributing
CNVs> 500 Kb
10 158 4 14
30 10 10 37
12 157 5 16
52 325 19 67
35 12 12 44
67 161 22 89a
34 17 17 47
36 190 51 180a
21151 2026
ts together comprise the “ADHD-meta cohort” andwere published by Elia et al [Elia et al., 2010] (“Elia
(“Lionel cohort”). The total number of CNVs and large CNVs (>500 Kb) are given, and then separate
omesharbor large CNVs. (B) CNVs arising in the genomesof individuals from three additional cohorts
giakouli et al. [Stergiakouli et al., 2012] (“Stergiakouli cohort”),Williams et al. [Williams et al., 2012],
in the genomesof individualswho aremembers of anapparently healthy control cohort, publishedby
not show corresponding totals for CNVs> 500 Kb; similarly the last column shows the number of
we show the maximum possible number of contributing individuals.
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Human genes were assigned to CNVs using the Ensembl Ensmart54
database. Supplemental Figures S1A and S1B describe the protocols
used to determinewhich geneswere affected by losses (“loss-genes”)
or gains (“gain-genes”), respectively. Briefly, for loss-genes we
required the disruption of a coding exon in all transcripts of that
gene, whereas we required gain-genes to be completely overlapped
by a CNV (Table II). This protocol is demonstrably less prone to
length biases associatedwith genes specifically expressed in the brain
and ensures that the protein product of a gene is affected by a CNV
whichever transcript is expressed [Webber, 2011; Noh et al., 2013].Removing Genes Overlapped by Common CNVs
in Apparently Healthy Individuals
We discarded CNV-genes present in individuals with ADHD if they
were also copy changed in the same direction by any of 24,478
common CNVs present in an apparently healthy control cohort of
2,026 individuals [Shaikh et al., 2009] (Table I), because variants
affecting thesegenesare less likely tobehighlypenetrant.Weidentified
these control CNV-genes as above (Supplemental Figure S1),
although control CNVs of all lengths were included (Table II).Mouse Genome Informatics (MGI) Phenotypes
Phenotypes exhibited during mouse gene model experiments
are described using the Mammalian Phenotype Ontology
(MPO; [Smith and Eppig, 2009]) and recorded in the MGI
resource (http://www.informatics.jax.org [Eppig et al., 2007];
downloaded 16/12/11). Using 1:1 human:mouse gene orthology
relationships defined by the MGI, we found 6,350 human
genes whose orthologues’ disruption yields a recorded phenotype
in mouse. The numbers of CNV-genes annotated with mouse
phenotypes in this manner are shown in Table II. WhenTABLE II. CNV-Genes Annotated With M
Cohort Gain-genes
Gain-genes minus
control
gain-genes
Gain-gen
with
phe
(A) ADHD-meta cohort
Elia cohort 57 53
Williams cohort 130 116
Lionel cohort 82 78
Total 264 244
(B) ADHD-replication cohort
Stergiakouli cohort 206 177
Williams (2) cohort 406 365
Jarick cohort 200 168
Total 594 537
(A) Numbers of CNV-genes in the ADHD-meta cohort and constituent cohorts. Separate totals are shown
are filtered out, and of the remaining CNV-genes we give the number of genes whose 1:1 mouse ortho
MouseGenome Informatics (MGI) database (termed “genes annotatedwithmousephenotypes”). (B)N
in (A).testing for the enrichment of MGI phenotypes among the mouse
orthologues of our CNV-genes, we focused on 158 phenotypes
in the MPO’s Behavioural/neurological phenotype category (see
Supplemental Information and Supplemental Figure S2). For
each phenotype, we compared the proportion of CNV-genes
whose orthologues’ yielded that phenotype in mouse with the
proportion of all genes, annotated with a mouse phenotype, for
which the same was true. P-values were obtained by applying
the hypergeometric test subject to a false discovery rate (FDR)
of <5% [Storey, 2002], and gene length biases checked (see
Supplemental Information).CNV Data for Patients With Hyperactivity and/or
Short Attention Span
Using DECIPHER ([Firth et al., 2009], see Supplemental Informa-
tion), in which clinical phenotypes are described using the London
Dysmorphology Database (LDD, [Fryns and de Ravel, 2002]), we
obtained CNV data for 22 patients withHyperactivity and/or Short
attention span (“Hyperactivity/SAS”; the “Hyper/SAS cohort”).
Within the LDD there is no single term that directly describes
ADHD. However, using an LDD-to-Human Phenotype Ontology
(HPO; [Robinson and Mundlos, 2010]) mapping (Supplemental
Figure S3), we can ontologically ascribemeaning to LDD terms and
relate them to the HPO phenotype of Attention deficit hyperactivity
disorder. Thus, in DECIPHER a patient with ADHD must be
described with one or both of the LDD terms Hyperactivity or
SAS; other keywords may be relevant to ADHD, but there is no
ontological requirement for them to be used to describe ADHD. A
limitation of the LDD-to-HPO mapping is that the relationship
between the LDD terms Hyperactivity/SAS and the HPO term for
ADHD is not symmetric; so a patient describedwith the LDD terms
Hyperactivity/SAS does not necessarily have ADHD. Nonetheless,
given the heterogeneity in ADHD phenotypes, identifying genesouse Phenotypes in ADHD Cohorts
es annotated
mouse
notypes Loss-genes
Loss-genes
minus control
loss-genes
Loss-genes
annotated with
mouse phenotypes
4 17 17 4
37 192 183 43
18 16 16 5
58 213 204 48
51 102 98 26
101 227 203 49
46 102 95 28
144 385 350 92
for gain- and loss-genes. We show the total number of CNV-genes, the total after control CNV-genes
logues are annotated with phenotypes from the Mammalian Phenotype Ontology (MPO) within the
umbers of CNV-genes in the ADHD-replication cohort and constituent cohorts. Columns are labeled as
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approach to dissecting the genetic basis of complex disease.
In line with the selection criteria for the studies providing our
ADHD-meta cohort [Elia et al., 2010; Williams et al., 2010; Lionel
et al., 2011], we selected theHyper/SAS cohort so that no individual
had autism or seizures. However, contrary to the selection criteria
used in the ADHD studies, we were unable to exclude intellectual
disability (ID; see Supplemental Information), and 21/22 cohort-
members also had ID.We directly address this issue using a human
brain-specific co-expression network described below (see Supple-
mental Information). An additional 100 phenotypes were present
among the cohort, but these were unlikely to introduce generalized
genetic enrichments unrelated to the phenotypes of interest because
each additional phenotype was possessed by only a minor fraction
of the cohort (see Supplemental Information and Supplemental
Figure S4). Therefore, we proceeded without further phenotype-
based exclusions. We required that CNVs were de novo and
>500 Kb, yielding 8 gains and 13 losses in 20 individuals (Supple-
mental Table SII). The gains arose in eight individuals: three with
Hyperactivity, three with Short attention span (SAS), and two with
both phenotypes. We noted that gains >500Kb present in the
Hyper/SAS cohort are longer than those arising in the ADHD-meta
cohort (Supplemental Figure S5; P¼ 0.003 [Wilcoxon rank sum
test]) and our statistical approach accounts for variability in CNV
length. As above, we identified 166 gain-genes not present in
control-cohort gain-genes, of which 55 (33%) were annotated
with a mouse phenotype in the MGI.BrainSpan Gene Expression Network
We obtained normalized gene expression data from BrainSpan
[Allen Institute for Brain Science] based on RNASeq of up to 16
brain regions (see Supplemental Information) from 41 individuals
aged from 8 weeks post-conception to 40 years. Only genes with an
RPKM 1 in 5% of the samples were included. A network was
built using R-packageWCGNA following the procedure (including
parameterization) recommended by the authors [Langfelder and
Horvath, 2008],where genes formnodes and the edges between two
genes are weighted with their expression correlation coefficient r.
Conservatively, we used only the sub-network comprising edges
with weight r 0.7, corresponding to the strongest 5% of edges
(5,679,999 edges, 13,953 genes). We checked our results when we
relaxed the threshold on r (see Supplemental Information).Calculating Empirical P-Values for the
Connectivity of Genes in the Brain
Co-Expression Network
Twenty-two genes contributed to enrichments, observed among
gain-genes in the ADHD-meta and Hyper/SAS cohorts, of genes
whose orthologues’ disruption yields abnormal learning/memory/
conditioning (l/m/c) phenotypes inmouse (Fig. 1).We refer to these
genes as “candidate-genes”. We tested the significance of
the connectivity observed among our 22 candidate-genes, within
the brain co-expression network, by calculating an empirical
P-value (Pemp): For 100,000 permutations, we randomly picked22 genes from the 439 genes whose orthologues when disrupted in
mouse yield l/m/c, calculated the sum of the weights of the edges
between them, and then counted the number of permutations, k,
where the sumof weights was greater than or equal to that observed
among the 22 candidate-genes; then Pemp¼ (kþ 1)/100,001.
We obtained 229 genes whose orthologues’ disruption yields
hyperactivity in mouse (termed “genes annotated with hyperactivi-
ty”; see Supplemental Information). To test if the 22 candidate-
geneswere significantly co-expressed in the human brainwith these
229 genes, when compared to genes whose mouse orthologues are
associated with other l/m/c phenotypes, we:i. Removed six genes present in both gene-sets, (GABRA5,
MAPK3, ARX, LIMK1, RAI1, and RYR3), and calculated the
sumof theweights of the edges fromthe remaining 16 candidate-
genes to the remaining 223genes annotatedwithhyperactivity in
mouse.ii. Obtained empirical 1-sided P-values from 100,000 permuta-
tions by picking at random 16 genes from 433 genes whose
mouse orthologues are associated with l/m/c phenotypes (six
genes excluded in step (i) were also excluded here); then
calculating the sum of the weights of the edges from the
randomly chosen genes to the 223 genes annotated with
hyperactivity.
We repeated this analysis for 13 and 12 candidate-genes from the
ADHD-meta andHyper/SAS cohorts, respectively.We also repeat-
ed the analysis for 56 genes that were duplicated among de novo
CNVs present in the genomes of 303 individuals with ID (but not
Hyperactivity/SAS, autism or seizures; obtained fromDECIPHER),
and whose orthologues’ disruption yields an l/m/c phenotype in
mouse (termed “ID-cohort l/m/c-genes”).
Finally, to test if the genes annotated with hyperactivity were
more connected to the candidate-genes than to the ID-cohort l/m/
c-geneswe repeated step (i), above, then obtained empirical 1-sided
P-values from 100000 permutations by:a. Picking at random 16 genes from a set of 66 genes comprised of
16 candidate-genes and 54 ID-cohort l/m/c-genes not annotated
with hyperactivity (four genes overlapped). (The six genes
excluded in step (i) were also excluded here).b. Calculating the sum of the weights of the edges from the
randomly chosen genes to the 223 genes annotated with
hyperactivity.
RESULTS
Behavioural Phenotypes Are Enriched Among
Genes That Are Overlapped by Gains in Patients
With ADHD
We sought to uncover molecular pathways whose genes were
disrupted by CNVs in ADHD. Combining data pertaining to
cohorts published in three studies (“Elia cohort” [Elia et al.,
FIG. 1. Gain-genes whose 1:1 mouse orthologues’ disruption yields abnormal learning/memory/conditioning in mouse. A: Thirteen gain-genes
in patients of the ADHD-meta cohort had mouse orthologues associated with l/m/c. The genes are shown in the innermost, blue, circle. Genes
are grouped according to the gains that overlap them as depicted in the middle, green, circle. The outermost circle shows which patients were
affected by which gain, and hence which genes were affected in each individual. Patients are colored by cohort: orange¼ Elia cohort,
red¼Williams cohort, and yellow¼ Lionel cohort. B: Twenty-two gain-genes whose orthologues’ disruption yields l/m/c. This is an expanded
set comprising the 13 genes shown in Figure 1A, and adding 12 gain-genes from the Hyper/SAS cohort (three of which are already present in
the original set of genes). The concentric circles provide information as described in Figure 1A, but the outermost circle now also shows
patients from the Hyper/SAS cohort; these individuals are depicted in bright pink.
TAYLOR ET AL. 1012010], “Williams cohort” [Williams et al., 2010], and “Lionel
cohort” [Lionel et al., 2011]; see Materials and Methods and
Supplemental Table SI), we considered those genes overlapped
by rare, predominantly inherited CNVs (“CNV-genes”) in 902
patients with ADHD (the “ADHD-meta cohort”).
We restricted our analysis to those CNVs> 500 Kb because (i)
large, rare CNVs have been implicated in several other neuro-
developmental disorders (including intellectual disability (ID) [de
Vries et al., 2005; Sharp et al., 2006], autism [Sebat et al., 2007;
Marshall et al., 2008], schizophrenia and bipolar disorder [Inter-
national Schizophrenia Consortium, 2008; Walsh et al., 2008;
Grozeva et al., 2010]); (ii) CNVs in this size-range have the greatest
burden inADHDcases compared to controls [Williams et al., 2010;
Stergiakouli et al., 2012; Williams et al., 2012]; and (iii), very large
variants are likely to be the most penetrant [Girirajan et al., 2011],
and thus may causally contribute to the disorder. Sixty-seven
individuals contributed 71 CNVs> 500 Kb (Table IA). After re-
moving genes overlapped by commonCNVs in healthy individuals
and thus unlikely to be particularly penetrant [Shaikh et al., 2009]
(see Materials and Methods and Table IC), we retained 244 “gain-
genes” and 204 “loss-genes” (genes overlapped by gains and losses,
respectively; see Materials and Methods and Table IIA).We then examined whether the ADHD CNV-genes were
enriched in genes whose orthologues’ mouse models were associ-
ated with particular phenotypes. As has previously been demon-
strated in analyses of behavioral disorders, mouse phenotypes are
informative for the analysis of human behavioral disorders because
they capture complex system properties such as behavior better
than more molecular gene annotations [Webber et al., 2009; Elia
et al., 2010; Noh et al. 2013]. We employed mouse phenotype data
from theMouseGenome Informatics (MGI) resource (http://www.
informatics.jax.org [Eppig et al., 2007]) to annotate the CNV-genes
(see Materials and Methods). In the ADHD-meta cohort, 58/244
(24%) gain-genes and 48/204 (24%) loss-genes had orthologous
genes whose disruption yields phenotypes in mouse (Table IIA).
Since ADHD is a behavioral disorder, we tested the ADHD-meta
cohort for an enrichment of CNV-genes whose orthologues were
associated with mouse phenotypes classed as “Behaviour/neurolog-
ical” within the MGI annotations. We found that Behavioural/
neurological phenotypes were enriched among the mouse ortho-
logues of gain-genes (28/58 (48%) genes, 1.5-fold enrichment,
P¼ 0.01), but not among the orthologues of loss-genes (12/48
(25%) genes, 0.76-fold change, P¼ 0.9). To refine the enrichment
identified among the gain-genes, we then tested 158 more specific
102 AMERICAN JOURNAL OF MEDICAL GENETICS PART BBehaviour/neurological phenotypes (see Materials and Methods,
Supplemental Information and Supplemental Figure S2). At an
FDR of 5%, only genes whose orthologues’ disruption yields an
abnormal learning/memory/conditioning (l/m/c) phenotype in
mouse were significantly enriched (13/58 (22%) genes, 3.2-fold
enrichment,P¼ 1 104).Gain-geneswhose orthologues’ disrup-
tion yields this phenotype were present in 11/67 (16%) of individ-
uals with CNVs> 500 Kb (Fig. 1A). We verified that the observed
functional enrichments among the mouse orthologues of gain-
genes were not caused by a length bias in the genes (see Supple-
mental Information). As a control experiment, we repeated the
analysis using a cohort of healthy individuals [Shaikh et al., 2009]:
among 90 genes which were overlapped by 71 rare gains >500Kb
and whose mouse orthologues had associated phenotypes, we
found no significant enrichment of genes whose orthologues’
disruption yields l/m/c in mouse (10/90 (11%) genes, 1.6-fold
enrichment, P> 0.05).Attempted Replication in a Second ADHD Cohort
While this studywas underway, three further data sets of rare CNVs
inADHDpatients were published, including 1,842 individualswith
ADHD not included in the ADHDmeta-cohort [Jarick et al., 2014;
Stergiakouli et al., 2012; Williams et al., 2012] (Supplemental
Table SI). Combining these new cohorts into the “ADHD-replica-
tion cohort”, we identified 537 gain-genes affected by large gains
(>500 Kb) inup to180patients (Tables IB and IIB), andwhichwere
not observed in common gains among controls. Among those 144
(27%) gain-genes whose mouse orthologues had associated phe-
notypes (Table IIB), there was no significant enrichment of genes
whose orthologues’ disruption yields l/m/c in mouse (8/144 (6%)
gain-genes associated with l/m/c, 0.8-fold change, P¼ 0.8). Among
the combined set of 192 analyzable gain-genes, arising in either
the ADHD-meta or ADHD-replication cohorts, there was a signif-
icant enrichment of genes whose orthologues’ disruption yields an
l/m/c phenotype in mouse (21/192 (11%) genes, 1.6-fold enrich-
ment, P¼ 0.02). However, this enrichment is largely formed by the
first ADHD meta-cohort.Gain-Genes in Patients With Hyperactivity
and/or Short Attention Span Are Associated
With Abnormal Learning/Memory/Conditioning
Next, we used theDECIPHERdatabase [Firth et al., 2009] to obtain
CNVs present in individuals with ADHD-related human pheno-
types (seeMaterials andMethods and Supplemental Information).
DECIPHER records genotypic and phenotypic data on individuals
with neurodevelopmental disorders and reports individual clinical
phenotypes using terms defined by the London Dysmorphology
Database (LDD, [Fryns and de Ravel, 2002]), wherein there is no
single term that directly describes ADHD. However, by mapping
LDD terms to the Human Phenotype Ontology (HPO, [Robinson
andMundlos, 2010]), we see that within DECIPHER an individual
with ADHDmust be described using the LDD termsHyperactivity
and/or Short attention span (abbreviated to “Hyperactivity/SAS”;
see Materials and Methods and Supplemental Figure S3). There-fore, we identified a cohort of 22 individuals with Hyperactivity/
SAS (herein termed the “Hyper/SAS cohort”), and whose genomes
harbored at least one de novo CNV (Supplemental Table SII). We
selected only de novo, rather than inherited, CNVs as these aremore
likely to be causal in these patients’ prominent neurodevelopmental
disorders and because of the variable reporting of inherited CNVs
within DECIPHER [Stankiewicz and Lupski, 2010; Veltman and
Brunner, 2012]. In accordance with the studies providing our
ADHD-meta cohort [Elia et al., 2010; Williams et al., 2010; Lionel
et al., 2011], we selected the cohort so that no individual presented
phenotypes associated with autism or seizures; however, 21/22
individuals in the Hyper/SAS cohort had ID (see Supplemental
Information; we return to address this later).
Filtering out CNVs< 500 Kb from the Hyper/SAS cohort left
eight gains in eight individuals (see Materials and Methods and
Supplemental Table SII), overlapping 166 genes not also present in
common gains among controls. Among the 55/166 (33%) gain-
genes for which orthologous mouse models and corresponding
phenotypes were available, 12 (22%) had orthologues whose dis-
ruption yields l/m/c in mouse (3.2-fold enrichment, P¼ 3 104).
Nineof the twelve gain-geneswerenot among those identified in the
ADHD-meta cohort (Fig. 1B), whereas the five individuals whose
gains harbored these genes were drawn from all three contributing
phenotype groups (Hyperactivity-only, SAS-only, andHyperactivi-
ty with SAS (Supplemental Table SIII)).Gain-Genes Associated With Abnormal
Learning/Memory/Conditioning Are
Co-Expressed in the Human Brain
Thephenotype l/m/c thatwas enriched among theADHD-meta and
Hyper/SAS gain-genes is a generalized mouse phenotype (encom-
passing 38 more specific phenotypes (Supplemental Figure S2))
that has been observed in the mouse models of 439 genes; only a
fraction of these genes’ orthologues may causally contribute to
ADHD. Consequently, we hypothesized that the 22 genes that
formed our enrichments (“candidate-genes”) might participate
in shared biological processes in humans; moreover, that these
biological processes are specific to this set of genes, and thus to
ADHD and ADHD-related phenotypes of Hyperactivity/SAS, as
compared to random sets of genes whose mouse orthologues are
associated with l/m/c.
To address this, we built a human gene co-expression network
using spatial and temporal maps of gene expression in the human
brain available from BrainSpan ([Allen Institute for Brain Science],
seeMaterials andMethods). In thisnetwork, the connectionbetween
two genes corresponds to the similarity in their brain expression
patterns. We found that the 22 candidate-genes were significantly
more co-expressed than random sets of 22 genes whose orthologues’
disruption yields l/m/c in mouse (P¼ 0.014; 14/22 candidate-genes
participate in the identified co-expression network (Fig. 2); see
Materials andMethods). Thus, themajorityof these candidate-genes
form a sub-network of genes that are tightly co-expressed within the
brain, as compared to random genes with l/m/c associations. We
asked if the co-expression network was primarily composed of co-
expressedgenes thatwere also co-localized to the samechromosomal
FIG. 2. Gain-genes whose 1:1 mouse orthologues’ disruption yields abnormal learning/memory/conditioning are expressed together in human
brain. Network of co-expression, in human brain, among 14 candidate-genes from the ADHD-meta and Hyper/SAS cohorts. Genes are drawn as
circles and colored by cohort according to the key shown in the figure, and unbroken purple lines connect co-expressed genes. We also show how
this network overlaps with an ADHD-associated glutamatergic network [Elia et al., 2012]: genes co-expressed with GRM5 are connected to the
gene by unbroken purple lines, and a protein-protein interaction between the protein products of GRM5 and MAPK3 is depicted with a dashed
gray line. Finally, we have annotated the co-expression network with protein-protein interaction data and indirect interaction data; dashed gray
lines connect pairs of candidate-genes whose protein products interact, and dotted gray lines connect genes with indirect interactions.
TAYLOR ET AL. 103region; itwasnot,withonly2/21(10%)ofpairsof co-expressedgenes
affected by the same gain CNV (gene-pairsCLIP2&GTF2IRD1, and
DOC2A & MAPK3; see Figs. 1B and Fig. 2).
As all of the individuals in the Hyper/SAS cohort also presented
with ID, any functional enrichment among genes affected by CNVs
in this cohort might be associated with these individuals’ ID
phenotype rather than theirADHD-related phenotypes. To address
this concern, we obtained a cohort of 303 individuals from DECI-
PHER who had ID but not Hyperactivity/SAS, autism or seizures,
and from that cohort identified 56 genes duplicated among de novo
CNVsandwhoseorthologues’ disruptionyields an l/m/cphenotype
in mouse (herein termed “ID-cohort l/m/c-genes”). We found that
the ADHD-meta cohort candidate-genes were significantly more
connected to the DECIPHER Hyper/SAS candidate-genes than to
the DECIPHER ID-cohort l/m/c-genes (P¼ 4 103; see Supple-
mental Information). This suggests that the l/m/c enrichment
among the mouse orthologues of Hyper/SAS cohort gain-genes
was related to these individuals’ ADHD-related phenotypes.ADHD and Hyperactivity/SAS Candidate-Genes
Are Co-Expressed With Genes Whose Mouse
Orthologues Are Associated With an ADHD
Face-Valid Phenotype
Previous work has suggested that face-valid mouse phenotypes for
ADHDarehyperactivity, reduced attention, and impulsivity [Bruno
et al., 2007]. The three MGI mouse phenotypes that correspond tothese human phenotypes are, respectively: hyperactivity, abnormal
latent inhibition of conditioning behavior, and abnormal impulsive
behavior control. We focused our analysis on just the set of 229
human genes whose orthologue’s disruption yields hyperactivity in
themouse (“genes annotated with hyperactivity”; see Supplemental
Information) because only six and four genes were annotated with
the other two phenotypes, respectively.
We asked whether the 22 candidate-genes were more tightly
co-expressed in the human brain with genes whose mouse ortho-
logues are associated with hyperactivity, as compared to other
genes whose mouse orthologues are associated with l/m/c pheno-
types. The mouse orthologues of 6 of the 22 candidate-genes are
associated with hyperactivity and for the purpose of this analysis
were removed from both sets of genes. Indeed, we found that the
remaining 16 candidate-geneswere significantlymore connected to
genes annotated with hyperactivity than were genes whose mouse
orthologues are associated with the more general l/m/c phenotype
(P¼ 7 103; Supplemental Figure S6; see Materials and Meth-
ods). Genes found in both the ADHD-meta cohort and the Hyper/
SAS cohort contributed to the connections (Table III and Supple-
mental Figure S6). The 13 candidate-genes from the ADHD-meta
cohort were significantly connected to the set of genes annotated
with hyperactivity in mouse (P¼ 0.02), even when the candidate-
genes only found in theHyper/SAS cohortwere excluded.Although
the connectionsbetween the12Hyper/SAS-cohort candidate-genes
and genes annotated with hyperactivity was not significant alone
(P¼ 0.06), they contributed to the increased significance reported
for the combined analyses.
TABLE III. Co-Expression Gene-Pairs Between Candidate-Genes, and Genes Whose Orthologues’ Disruption Yields hyperactivity in Mouse
Cohort
Number of cohort
candidate-genes co-expressed
with genes annotated with hyperactivity
Number of co-expressed
gene-pairs between cohort
candidate-genes and genes annotated with hyperactivity
ADHD-meta 7 117
Hyper/SAS 4 80
Both 2 27
For each cohort we show the number of candidate-genes co-expressed with genes whose 1:1 orthologues’ disruption yields hyperactivity in mouse (“genes annotated with hyperactivity”), and then we
show the number of co-expressed gene-pairs between the sets of genes. The last row of the table gives the statistics for the candidate-genes that are present in both the ADHD-meta and the Hyper/SAS
cohorts.
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ADHD candidate genes with hyperactivity genes was specific to
ADHD rather than ID. For this, we asked whether the 56 DECI-
PHER ID-cohort l/m/c-genes were also significantly connected to
the set of genes annotatedwith hyperactivity inmouse, as compared
to all genes annotated with l/m/c in mouse (see Materials and
Methods); they were not (P¼ 0.3). Crucially, we found that
genes annotated with hyperactivity in mouse were significantly
more connected to the ADHD candidate-genes than to the
DECIPHER ID-cohort l/m/c-genes (P¼ 0.02; see Materials and
Methods).DISCUSSION
In this study, we explored the hypothesis that distinct CNVs give
rise to ADHD by affecting genes participating in shared biological
processes, the perturbation of which causes the disorder. Analyzing
genes in duplications from individuals with ADHD and ADHD-
related phenotypes, we identified an enrichment of duplicated
genes whose loss in the mouse is associated with abnormal learn-
ing/memory/conditioning phenotypes (l/m/c), yielding 22 candi-
date-genes of interest.We found that these 22 l/m/c candidate-genes
are co-expressed spatially and temporally within the human brain
suggesting that they participate in shared biological processes.
Finally, we found that the 22 candidate genes are co-expressed
with genes whose disruption is associated with hyperactivity, an
integral phenotype in face-valid mouse models of ADHD, and that
this association is significantly stronger for these ADHD candidate
genes as compared to genes similarly selected fromCNVs identified
within individuals with ID.
Our enrichment was found among gain-genes, but the associ-
ated mouse models result from gene losses; moreover, we did not
find a specific enrichment of hyperactivity phenotypes among
gain-genes, but of a more general l/m/c phenotype. These results
are consistent with examples of genes whose deletions predispose
to one set of neuropsychiatric disorders but whose duplications
influence another. For example, the disruption of SHANK3 has
been implicated ASD, ID, and SCZ whereas its over-expression in
the mouse causes manic-like behavior [Bonaglia et al., 2006;
Durand et al., 2007; Moessner et al., 2007; Gauthier et al., 2009;
Gauthier et al., 2010; Grabrucker et al., 2011; Han et al., 2013].
Corroboratively, 11 of our 22 candidate-genes have been impli-cated in ASD or SCZ or other neurological or neuropsychiatric
syndromes by a variety of genetic variants (Supplemental Tables
SIV and SV). It is likely, therefore, that some of these genes are
dosage-sensitive so that increased or decreased levels are delete-
rious [Gout et al., 2010], as has been shown for proteins at the
synapse [Sugiyama et al., 2005].
We were unable to replicate the enrichment of l/m/c-associated
genes among the gain-genes of a second, larger, cohort of
ADHD patients, which may indicate that our initial result was a
false positive. However, to argue against this, we highlight
the concordances in gene expression patterns between the candi-
date genes similarly identified in the ADHD-meta cohort and the
DECIPHERHyper/SAS cohort, and between these genes and those
that influence hyperactivity phenotypes in themouse.We note that
mouse phenotypes have only been investigated for the orthologues
of ~1/3rd of human genes, diminishing the power of our approach.
Of these, the mouse orthologues of only 2,089 genes are annotated
with Behaviour/neurological phenotypes and, more specifically,
only 439 genes with an l/m/c phenotype. Furthermore, of the 67
patients considered in the ADHD-meta cohort, our findings are
able to provide a causal hypothesis for 11 (16%) patients (Fig. 1A).
The unexplained 84% of patients may possess genetic variants of a
type not considered in this study, and affecting genes that partici-
pate in the network reported here. However, it may also be that our
studyhas insteadalightedupononlyone amongmultiplemolecular
mechanisms underlying ADHD that may not be similarly repre-
sented in other cohorts.
Nonetheless, the enrichment was also found among a set of de
novo-gain-genes present in individuals with human phenotypes
of Hyperactivity and Short attention span (SAS), obtained from
DECIPHER. There are two considerations regarding the use of
this cohort. The first is that all of the patients in the DECIPHER
cohort also had ID and that any functional enrichment among
genes affected by CNVs in this cohort might be associated with
these individuals’ ID phenotype rather than their ADHD-related
phenotypes. The heterogeneity and complexity of ID and ADHD,
and the potential impact that the disorders have on one another
in individuals comorbid for them, means that we cannot rule this
out. However, using our brain-specific co-expression network,
we found evidence to suggest that the l/m/c enrichment among
the mouse orthologues of Hyper/SAS cohort gain-genes
was related to these individuals’ ADHD-related phenotypes.
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mild ID are not a clinically distinct ADHD subgroup [Ahuja
et al., 2013]. The second consideration regarding our use of this
cohort is that Hyperactivity and SAS are not synonymous
with ADHD; however, they are immediate ontological
ancestors of ADHD, and any patient with ADHD recorded in
DECIPHER must be described using these terms (Supplemental
Figure S3). Moreover, we propose that if we are to establish a
molecular basis for ADHD, then it is vital to study the shared
processes among genes implicated in both ADHD and ADHD-
related phenotypes. The co-expression of the two sets of candi-
date genes in the brain, and with genes whose orthologues’
disruption in the mouse yields hyperactivity phenotypes,
supports a shared ADHD-relevant molecular etiology for indi-
viduals from both the ADHD meta-cohort and the Hyper/SAS
cohort.
The identified co-expression network included 14 of 22 can-
didate-genes, comprising genes from both cohorts. We placed
this co-expression network in the context of previously identified
ADHD-associated glutamatergic and neurodevelopmental net-
works [Poelmans et al., 2011; Elia et al., 2012]. Three of the genes
in the network (CHL1, STIM2, and SLC12A6) were co-expressed
with the metabotropic glutamate receptor GRM5, and MAPK3
had a known protein-protein interaction with another metabo-
tropic glutamate receptor, GRM1 (Fig. 2). In addition, two of
the co-expressed 14 genes, MAPK3 and SERPINI1, participated
in the neurodevelopmental network for ADHD proposed by
Poelmans et al., [Poelmans et al., 2011]. We also annotated
the co-expression network with known protein-protein and
indirect gene-gene interactions: the two clusters formed by the
14 candidate-genes were connected by an interaction between the
protein products of STX1A (part of the SNARE complex) and
APBA2 (Fig. 2). APBA2 is part of a multi-protein complex, which
probably functions as an intermediate in neurotransmitter vesicle
docking [Biederer and Sudhof, 2000; Dulubova et al., 2007; Kirov
et al., 2008]; this complex also includes members of the SNARE
complex. Additionally, in mouse brain, CHL1 has been shown to
have a role in the selective activation of the presynaptic machin-
ery chaperoning the SNARE complex [Andreyeva et al., 2010],
thus providing evidence of an indirect interaction between CHL1
and STX1A (Fig. 2).
In conclusion,we have identified a previously unknownnetwork
of co-expressed genes preferentially disrupted among patients with
ADHD or ADHD-related phenotypes, which both proposes a
common molecular etiology and, if confirmed, provides targets
for the development of therapeutic interventions.ACKNOWLEDGEMENTS
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